Get the Stockscreener App
0.0807
4.60%
-0.0041
Profusa Inc stock is traded at $0.0807, with a volume of 2.27M.
It is down -4.60% in the last 24 hours and down -54.29% over the past month.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
See More
Previous Close:
$0.0848
Open:
$0.081
24h Volume:
2.27M
Relative Volume:
0.10
Market Cap:
$6.97M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-33.58%
1M Performance:
-54.29%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.0805
$0.0829
1-Week Range:
$0.0806
$0.1175
52-Week Range:
$0.0651
$2.22
Profusa Inc Stock (PFSA) Company Profile
Name
Profusa Inc
Sector
Industry
Phone
212-494-9022
Address
207 WEST 25TH ST, 9TH FLOOR, NEW YORK
Compare PFSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
0.0807 | 8.64M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
128.41 | 219.88B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.54 | 141.54B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.37 | 133.39B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.75 | 124.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.69 | 48.84B | 5.88B | 1.34B | 799.60M | 2.3489 |
Profusa Inc Stock (PFSA) Latest News
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Profusa (NASDAQ: PFSA) outlines reverse split plan to address Nasdaq listing rules - Stock Titan
Profusa, Inc.Common Stock (NQ: PFSA - FinancialContent
Profusa restructures senior secured convertible notes - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Profusa expands European footprint with French distributor partnership By Investing.com - Investing.com Nigeria
Profusa expands European footprint with French distributor partnership - Investing.com India
Profusa Bolsters European Commercial Network with New French Distributor, MedSell - The Manila Times
Profusa Bolsters European Commercial Network With New French Distributor, MedSell - 富途牛牛
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Profusa stock whipsaws: PFSA dips premarket after 78% surge on debt restructuring - ts2.tech
Nio, Profusa, Nike, FTAI Aviation And Under Armour: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Profusa (PFSA) Stock Analysis Report | Financials & Insights - Benzinga
Profusa Stock Soars—To 12 Cents—On Debt Restructuring - Sahm
Profusa (PFSA) Stock: Announces Key Changes to Senior Secured Convertible Notes for Stronger Financial Health - parameter.io
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Nasdaq Trading Activity: Profusa Leads High-Volume Movers on December 30, 2025News and Statistics - IndexBox
Profusa amends securities purchase agreement to allow for $5 million note sale - Investing.com Nigeria
Here’s Why Profusa Stock (PFSA) Rocketed Today - TipRanks
US Stocks Lower; Home Price Growth Eases in October - Sahm
Profusa Restructures Senior Secured Convertible Notes; Shares Jump Pre-Bell - marketscreener.com
Profusa restructures convertible note to reduce dilution, increase flexibility - Investing.com
Profusa restructures convertible note to reduce dilution, increase flexibility By Investing.com - Investing.com South Africa
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 - The Manila Times
Profusa Signs Amendment No. 3 to Securities Purchase Agreement With Ascent Partners Fund - TradingView — Track All Markets
[8-K] Profusa, Inc. Reports Material Event | PFSA SEC FilingForm 8-K - Stock Titan
Digital health firm revamps debt terms to reduce share dilution - Stock Titan
PFSA SEC FilingsProfusa Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Profusa amends equity deal and convertible note terms - MSN
[424B3] Profusa, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Profusa amends securities agreements with Ascent Partners Fund - Investing.com India
Profusa Amends Equity Deal and Convertible Note Terms - TipRanks
Profusa amends securities agreements with Ascent Partners Fund By Investing.com - Investing.com UK
Profusa Updates Multiple Financing Agreements With Ascent Partners Fund - TradingView — Track All Markets
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Profusa (NASDAQ:PFSA) versus ReShape Lifesciences (OTCMKTS:RSLSD) Financial Contrast - Defense World
Profusa’s Lumee oxygen monitoring meets key endpoints in PAD study By Investing.com - Investing.com Nigeria
Profusa’s Lumee oxygen monitoring meets key endpoints in PAD study - Investing.com
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - The Manila Times
Profusa U.S. study met primary end points as presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - marketscreener.com
Profusa U.S. Study Met Primary End Points As Presented At Late Breaking Clinical Trials At Paris Vascular Insights 2025 - TradingView — Track All Markets
Profusa (Nasdaq: PFSA) U.S. Lumee PAD study hits endpoints, backs potential FDA filing - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - The Manila Times
Profusa (Nasdaq: PFSA) to share US pilot PAD Lumee data at LINC 2026 in Leipzig - Stock Titan
The growth track for Profusa Inc (PFSA) has changed recently - setenews.com
Profusa, Inc. Common Stock (PFSA) -5.4% in Intraday Trading: Decline Despite Positive Clinical Update - Stocks Telegraph
Q&A: Real-time digital healthcare for 2026 - Digital Journal
Top investors say TSS Inc (TSSI) ticks everything they need - Setenews
How does Profusa Inc (PFSA) change from a tortoise to a hare? - Setenews
Profusa to Present Late Breaking U.S. Based Clinical Trial Update at Paris Vascular Insights 2025 - marketscreener.com
Profusa Inc Stock (PFSA) Financials Data
There is no financial data for Profusa Inc (PFSA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.45%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):